GLP-1 drugs and fatty liver: what the MASH approvals mean

The disease no one was treating

Fatty liver is everywhere. Somewhere between 25 and 38% of adults globally have fat accumulating in their liver cells — a condition doctors now call MASLD (metabolic dysfunction-associated steatotic liver disease, formerly NAFLD). Most of those people feel nothing. It shows up on an abdominal ultrasound ordered for something else, gets noted in the chart, and generates advice to lose weight and cut back on alcohol.

That advice is usually where the conversation stops. Because until 2024, no drug had ever been approved to treat it.

The more serious problem is MASH — metabolic-associated steatohepatitis, formerly called NASH. MASH is what happens when simple fat accumulation progresses to active inflammation, liver cell death, and fibrosis. About 20% of people with fatty liver eventually develop MASH. It affects roughly 6–8% of all adults worldwide. Without treatment, it can progress to cirrhosis, liver failure, and hepatocellular carcinoma. It is also, until recently, a disease with essentially no approved pharmacologic intervention.

Semaglutide becomes the first GLP-1 approved for MASH

On August 15, 2025, the FDA granted accelerated approval to semaglutide 2.4mg weekly — the Wegovy dose — for adults with MASH and moderate to advanced liver fibrosis, staged F2 or F3. That made semaglutide the first GLP-1 receptor agonist ever approved for a liver indication.

It was not the first drug approved for MASH overall. Resmetirom (Rezdiffra), an oral thyroid hormone receptor-β agonist made by Madrigal, got there first in March 2024. But resmetirom and semaglutide operate through entirely different mechanisms, and the efficacy numbers look quite different.

The FDA based the semaglutide approval on interim results from the Phase 3 ESSENCE trial — a 240-week study that enrolled 800 adults with biopsy-confirmed MASH and F2–F3 fibrosis. Interim data at 72 weeks was compelling enough to act on.

What the ESSENCE trial found

The primary endpoint: resolution of MASH without worsening of liver fibrosis, confirmed by biopsy. Not a blood test. Not an imaging marker. A needle in the liver, before and after.

At week 72, 62.9% of semaglutide participants hit that endpoint. On placebo, 34.3% did. That is a 28.7 percentage-point gap — larger than most liver disease trials have ever produced on a histologic endpoint.

The secondary endpoint showed 36.8% of semaglutide patients achieving at least one stage of fibrosis improvement without MASH worsening, versus 22.4% on placebo. And 32.7% hit both outcomes simultaneously — full MASH resolution and meaningful fibrosis reversal. The placebo rate on that combined endpoint was 16.1%.

These are biopsy-confirmed results. The trial required liver biopsies at baseline and again at week 72, which is the accepted gold standard for MASH assessment. When 62.9% of participants hit a histologic resolution endpoint, that is a real signal. The number compares favorably not just to resmetirom but to the entire prior history of MASH drug development, which is littered with late-stage failures.

Why this is better than the existing option

Resmetirom benefits roughly 25–30% of patients on key histologic endpoints. Semaglutide hit 62.9% on MASH resolution. Both drugs are approved for the same F2–F3 noncirrhotic population. That gap matters clinically.

The American Association for the Study of Liver Diseases updated its practice guidance in November 2025, positioning semaglutide explicitly in the treatment algorithm for MASH — a fast turnaround from approval to guideline recommendation. The 2026 EASO update did the same for both semaglutide and tirzepatide, the first time GLP-1 drugs appeared in a major European liver disease guideline.

There is also the access question. Resmetirom is a drug people need to specifically seek out. Semaglutide is already in the hands of millions of patients being treated for obesity and cardiovascular disease. For a meaningful portion of them, MASH treatment has been happening as a consequence of a prescription they already hold — they just did not know it.

Tirzepatide joins it in 2026

In early 2026, the FDA granted accelerated approval to tirzepatide for MASH, based on Phase 2 results from the SYNERGY-NASH trial. That made two GLP-1 drugs — the same two that now dominate the weight loss and diabetes market — approved for fatty liver disease.

This is not entirely surprising. Tirzepatide's GIP activity appears to add direct liver benefit beyond what GLP-1 alone provides. The SYNERGY-NASH Phase 2 data showed strong fibrosis improvement rates, and Phase 3 confirmatory trials are running through 2026. If those confirm, tirzepatide may end up with a label that is easier to justify than semaglutide's — Phase 3 rather than accelerated approval.

For a comparison of the two drugs on their primary obesity indications, see our semaglutide vs. tirzepatide breakdown. The liver data is one more dimension where tirzepatide's dual mechanism appears to add something semaglutide cannot.

Who should be paying attention

MASH is frequently silent until advanced stages. The typical patient: middle-aged, carrying extra weight, possibly with prediabetes or type 2 diabetes, with liver enzymes that have run slightly elevated on routine bloodwork for years. The ALT gets flagged, an ultrasound confirms a fatty liver, and nothing else happens. That is the standard trajectory.

If you are on a GLP-1 for obesity or diabetes and you have a history of elevated liver enzymes or a documented fatty liver on imaging, it is worth asking your doctor whether a MASH workup is appropriate. The diagnosis requires a liver biopsy, which is invasive, so clinicians typically reserve it for patients with elevated enzymes plus imaging evidence plus risk factors for fibrosis. Non-invasive scoring tools — like the FIB-4 index — can help identify who is worth biopsying.

The drug you may already be taking could be treating your liver. That is a question worth raising.

What this does not mean

The ESSENCE approval is not a broad liver health endorsement. Semaglutide is approved for MASH with F2–F3 fibrosis — not for simple fatty liver without inflammation, not for cirrhosis, and not as a prophylactic against liver disease in people without a diagnosis. The relevant dose is 2.4mg weekly, which is the Wegovy formulation. Ozempic, typically dosed at 1mg weekly for diabetes, was not the trial drug and does not carry the MASH indication.

The 72-week ESSENCE results are interim data from a 240-week trial. Liver fibrosis takes years to develop and years to reverse. How much fibrosis continues to improve — or whether it stays improved — past the first 72 weeks is not yet known. The longer-term results will read out through 2028 and beyond.

But the short version is this: for a condition that had no approved treatment for decades, two GLP-1 drugs are now approved for it, and one of them shows a 62.9% histologic resolution rate. That is a meaningful shift in what can be offered to patients who have been told to just lose weight and hope for the best.

Worth reading alongside this: retatrutide's Phase 2 trial showed an 86% reduction in liver fat in a substudy — a number that, if confirmed in Phase 3, may eventually make the triple agonist the liver disease drug of choice as well. And the SYNCHRONIZE-MASLD Phase 3 trial published at ADA 2026 added another data point: survodutide, which combines glucagon and GLP-1 receptor agonism, normalized liver fat in 61% of MASLD patients — different mechanism, different drug, similar directional signal on the liver.